China Generic Drug Registrations Nose Dive
This article was originally published in PharmAsia News
According to recent China State FDA figures, since the revised drug registration rule took effect last October, applications for generic drug registrations have nose dived while applications for new drugs have grown. During this one-year period, China has accepted applications of 553 new drugs, 155 formulation changes, 825 generic drugs, 502 imported drugs and 225 biological products. The generics figure contrasts sharply with the over 8,000 approved in 2005. SFDA officials think the trend indicates that new policies have held in check applications based on copying or modifying drugs with low R&D technology. The agency will publicize at the end of this year new drug applications approved since last October. (Click here for more - Chinese Language)
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.